Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
PHENURONE (phenacemide) is an oral small-molecule tablet approved in 1951 as an anticonvulsant. The mechanism of action and specific indications are not documented in available data, limiting current clinical relevance. This legacy product operates in a mature, highly competitive therapeutic space.
As LOE approaches, commercial teams face contraction; headcount will likely decline and focus will shift to legacy maintenance and managed transition.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PHENURONE offers limited career advancement as the product approaches LOE with zero linked job openings. Professionals on this brand will focus on managing decline, ensuring compliance, and potentially transitioning to growth-stage assets within AbbVie's portfolio.
Worked on PHENURONE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.